Cargando…

Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer

Objectives: The aim of study was to compare salivary and serum concentrations of interleukin 1 beta (IL-1β), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) in patients with oral leukoplakia, oral cancer and healthy controls. Study design: Eighty eight patients (28 with oral cancer, 29...

Descripción completa

Detalles Bibliográficos
Autores principales: Brailo, Vlaho, Vucicevic-Boras, Vanja, Lukac, Josip, Biocina-Lukenda, Dolores, Zilic-Alajbeg, Iva, Milenovic, Aleksandar, Balija, Melita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medicina Oral S.L. 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448188/
https://www.ncbi.nlm.nih.gov/pubmed/21743397
http://dx.doi.org/10.4317/medoral.17323
_version_ 1782244228887216128
author Brailo, Vlaho
Vucicevic-Boras, Vanja
Lukac, Josip
Biocina-Lukenda, Dolores
Zilic-Alajbeg, Iva
Milenovic, Aleksandar
Balija, Melita
author_facet Brailo, Vlaho
Vucicevic-Boras, Vanja
Lukac, Josip
Biocina-Lukenda, Dolores
Zilic-Alajbeg, Iva
Milenovic, Aleksandar
Balija, Melita
author_sort Brailo, Vlaho
collection PubMed
description Objectives: The aim of study was to compare salivary and serum concentrations of interleukin 1 beta (IL-1β), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) in patients with oral leukoplakia, oral cancer and healthy controls. Study design: Eighty eight patients (28 with oral cancer, 29 leukoplakia, and 31 healthy controls) were included in this study. Cytokine concentrations were measured by commercial enzyme linked immunoassay. Results: Salivary IL-1β and IL-6 were significantly higher in oral cancer patients than in patients with leukoplakia and control group (p<0.05). No differences in concentrations of salivary TNF-α between either of the groups were observed. Serum concentrations of IL-1β were below level of detection in all but two participants. No significant differences between the groups were observed in serum concentrations of IL-6. Serum TNF-α was significantly higher in control subjects than in oral cancer patients. Conclusions: Patients with oral cancer have elevated levels of inflammatory cytokines in their saliva. Whether this elevation can be used for monitoring the malignant transformation of oral leukoplakia remains to be answered by further follow up studies. Key words: Cytokines, oral, leukoplakia, cancer.
format Online
Article
Text
id pubmed-3448188
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medicina Oral S.L.
record_format MEDLINE/PubMed
spelling pubmed-34481882012-10-11 Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer Brailo, Vlaho Vucicevic-Boras, Vanja Lukac, Josip Biocina-Lukenda, Dolores Zilic-Alajbeg, Iva Milenovic, Aleksandar Balija, Melita Med Oral Patol Oral Cir Bucal Research-Article Objectives: The aim of study was to compare salivary and serum concentrations of interleukin 1 beta (IL-1β), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) in patients with oral leukoplakia, oral cancer and healthy controls. Study design: Eighty eight patients (28 with oral cancer, 29 leukoplakia, and 31 healthy controls) were included in this study. Cytokine concentrations were measured by commercial enzyme linked immunoassay. Results: Salivary IL-1β and IL-6 were significantly higher in oral cancer patients than in patients with leukoplakia and control group (p<0.05). No differences in concentrations of salivary TNF-α between either of the groups were observed. Serum concentrations of IL-1β were below level of detection in all but two participants. No significant differences between the groups were observed in serum concentrations of IL-6. Serum TNF-α was significantly higher in control subjects than in oral cancer patients. Conclusions: Patients with oral cancer have elevated levels of inflammatory cytokines in their saliva. Whether this elevation can be used for monitoring the malignant transformation of oral leukoplakia remains to be answered by further follow up studies. Key words: Cytokines, oral, leukoplakia, cancer. Medicina Oral S.L. 2012-01 2011-07-15 /pmc/articles/PMC3448188/ /pubmed/21743397 http://dx.doi.org/10.4317/medoral.17323 Text en Copyright: © 2012 Medicina Oral S.L. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research-Article
Brailo, Vlaho
Vucicevic-Boras, Vanja
Lukac, Josip
Biocina-Lukenda, Dolores
Zilic-Alajbeg, Iva
Milenovic, Aleksandar
Balija, Melita
Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer
title Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer
title_full Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer
title_fullStr Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer
title_full_unstemmed Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer
title_short Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer
title_sort salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer
topic Research-Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448188/
https://www.ncbi.nlm.nih.gov/pubmed/21743397
http://dx.doi.org/10.4317/medoral.17323
work_keys_str_mv AT brailovlaho salivaryandseruminterleukin1betainterleukin6andtumornecrosisfactoralphainpatientswithleukoplakiaandoralcancer
AT vucicevicborasvanja salivaryandseruminterleukin1betainterleukin6andtumornecrosisfactoralphainpatientswithleukoplakiaandoralcancer
AT lukacjosip salivaryandseruminterleukin1betainterleukin6andtumornecrosisfactoralphainpatientswithleukoplakiaandoralcancer
AT biocinalukendadolores salivaryandseruminterleukin1betainterleukin6andtumornecrosisfactoralphainpatientswithleukoplakiaandoralcancer
AT zilicalajbegiva salivaryandseruminterleukin1betainterleukin6andtumornecrosisfactoralphainpatientswithleukoplakiaandoralcancer
AT milenovicaleksandar salivaryandseruminterleukin1betainterleukin6andtumornecrosisfactoralphainpatientswithleukoplakiaandoralcancer
AT balijamelita salivaryandseruminterleukin1betainterleukin6andtumornecrosisfactoralphainpatientswithleukoplakiaandoralcancer